CODX240628P2500
- 1.15
- 0.000.00%
Co-diagnostics Newsroom
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers Across 15 U.S. States
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development ...
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...
H.C. Wainwright Maintains Co-diagnostics(CODX.US) With Hold Rating, Maintains Target Price $2
H.C. Wainwright analyst Yi Chen maintains $Co-diagnostics(CODX.US)$ with a hold rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success rate of 0.0% and a to
Express News | HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $2 Price Target
Express News | Co-Diagnostics Submits FDA Application For 510(k) Clearance Of Co-Dx PCR Pro Instrument And OTC COVID-19 Test; POC Clearance And Additional Tests To Follow
Express News | Co-Diagnostics, Inc. Submits First FDA 510(K) Application for Co-Dx Pcr Pro Platform
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersCalidi Biotherapeutics (AMEX:CLDI) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million. Entero Therapeutics (NASDAQ:E
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results.G-III Apparel Group posted adjusted earn
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersVirax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37%
Co-Diagnostics Is Maintained at Neutral by HC Wainwright & Co.
Co-Diagnostics Is Maintained at Neutral by HC Wainwright & Co.
Co-Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 80.18% HC Wainwright & Co. $2.5 → $2 Maintains Neutral 03/15/2024 125.23% HC Wainwright & Co. $
Express News | Co-Diagnostics, Inc. : H.c. Wainwright Cuts Target Price to $2 From $2.5
Earnings Call Summary | Co-diagnostics(CODX.US) Q1 2024 Earnings Conference
The following is a summary of the Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript:Financial Performance:Co-Diagnostics Q1 2024 recorded a revenue of $0.5 million, a decrease from the prev
Co-Diagnostics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Co-Diagnostics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript
Co-diagnostics | 10-Q: Quarterly report
Co-Diagnostics Q1 2024 GAAP EPS $(0.31) Misses $(0.21) Estimate, Sales $467.854K Miss $3.050M Estimate
Co-Diagnostics (NASDAQ:CODX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 55 percent decrease over losses of $(0.20
Express News | Co-Diagnostics Q1 Revenue USD 500 Thousand
Express News | Co-Diagnostics Q1 Adjusted Ebitda USD -8.4 Million
Express News | Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results